ArticleClinical cancer research : an official journal of the American Association for Cancer Research2013

PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in imatinib mesylate-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.

Girija Dasmahapatra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.